報價延遲最少15分鐘:2024/12/23 22:12 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.07 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.45/-1.52
|
|
企業價值
13.68M
|
| 資產負債 |
|
每股賬面淨值
-1.06
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:12 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases. |